News

Alkem Laboratories announced the incorporation of a wholly owned subsidiary in the name of Alkem Pharma Trading FZCO in Dubai, UAE. The subsidiary will undertake export of company`s products to African, South East Asian and non-UAE markets.

 Alkem Laboratories announced the launch of A to Z Daily, an everyday multivitamin supplement for adults, for providing holistic nutritional support to the body and mind. A to Z Daily tablets are formulated with a total of 26 essential vitamins, minerals and botanicals to provide balanced nutritional support. The key vitamins and minerals include Vitamin B complex, Vitamin D3, Vitamin C, Zinc, and Iron that help in boosting energy levels, reducing fatigue and improving immunity. The product also contains clinically researched botanicals such as Ashwagandha, Bacopa monnieri (Brahmi), Panax ginseng, and an amino acid L-theanine, which help in managing stress and anxiety, improving sleep quality and supporting the cognitive function.Commenting on the launch, Dr. Vikas Gupta, Chief Executive Officer, Alkem, said, �Our current lifestyles are placing sustained demands not just on physical health but also on mental well-being. People are increasingly experiencing stress, fatigue, and reduced ability to stay focused. Nutritional supplementation can play a supportive role in addressing these challenges when designed thoughtfully. A to Z Daily brings together essential ingredients to provide a balanced, everyday support for both body and mind. It is positioned not as a quick fix, but as a consistent, long-term approach for people seeking to manage everyday stress while improving overall vitality.�

Alkem Laboratories announced that the United States Food and Drug Administration (USFDA) has completed a Pre-Approval Inspection (PAI) on 13 February, 2026 at the manufacturing facility of Enzene Biosciences (Enzene), a subsidiary of the Company in India located at Chakan, Pune. At the conclusion of the inspection, the USFDA issued a Form 483 with 6 procedural observations. Enzene has achieved Zero observations related to data integrity - a critical validation of Enzene`s quality systems and the reliability of regulatory filings. Enzene is in the process of preparing and submitting its response to the USFDA within the stipulated timeline and has initiated appropriate corrective and preventive actions. Powered by Capital Market - Live News

Alkem Laboratories announced that the Board of Directors of the Company at its meeting held on 13 February 2026, inter alia, have recommended the interim dividend of Rs 43 per equity Share (i.e. 2150%) , subject to the approval of the shareholders.Powered by Capital Market - Live News

Net profit of Alkem Laboratories rose 1.63% to Rs 636.02 crore in the quarter ended December 2025 as against Rs 625.82 crore during the previous quarter ended December 2024. Sales rose 10.74% to Rs 3736.82 crore in the quarter ended December 2025 as against Rs 3374.28 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales3736.823374.28 11 OPM %22.1622.51 - PBDT929.00816.35 14 PBT833.99731.07 14 NP636.02625.82 2 Powered by Capital Market - Live News